Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274508 · ClinicalTrials.gov registry record · Phase 3
Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 261
- Enrollment target
NCT00274508 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 261 participants.
The verdict
NCT00274508, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 261 participants
- Enrollment target
Study Summary
To investigate whether tiotropium (Spiriva) improves exercise endurance in patients with COPD
Interventions
- DRUG tiotropium bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2000-10-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274508
The ClinicalTrials.gov registry entry for NCT00274508 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tiotropium bromide is the first listed.
NCT00274508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00274508 about?
NCT00274508 is a clinical study titled "Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients". To investigate whether tiotropium (Spiriva) improves exercise endurance in patients with COPD
What is the current status of trial NCT00274508?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 261 participants. The study started on 2000-10-10.
What interventions are being tested in trial NCT00274508?
The interventions under investigation include: tiotropium bromide (DRUG).
Who is sponsoring clinical trial NCT00274508?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.